ABBV生命科学与高端医疗● Live Quotes Active

AbbVie Inc.

No mega hedge funds in our coverage currently report a major 13F position in this stock

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Wall St Sentiment
0%Bullish
+0/0/-0
Total Tracked Shares
0shares

Based on SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀ABBV SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
A 级(81分)
RS Rating
81/ 99
Pattern Setup
Extended
Pivot Benchmark
$267.75Support: $254.36

📌 Business Moat Summary:AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in ABBV.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade A, RS Rating 81).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% 均仓
0 f2026 Q2
0% 均仓
0 f2026 Q1
0% 均仓
0 f2025 Q4
0% 均仓
0 f2025 Q3
0% 均仓
0 f2025 Q2
0% 均仓
0 f2025 Q1
0% 均仓
0 f2024 Q4
0% 均仓
0 f2024 Q3
2026 Q2|Report Date: 2026-06-30
Holding Funds: 0 家Total Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock

Examine each hedge fund holding this ticker, weight, shares, and recent action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade ABBV?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.

ABBV (AbbVie Inc.) Institutional 13F Ownership & SGDC Growth Analysis 2026 | WhaleTracker